Diagnosis and management of primary biliary cirrhosis

Ahmad H. Ali, Elizabeth J. Carey, Keith D. Lindor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized histologically by destruction of intrahepatic bile ducts and serologically by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC are increasing. Fatigue and pruritus are common symptoms in PBC, although the proportion of asymptomatic PBC is increasing due to the widespread use of screening biochemical tests and antimitochondrial antibody assays. PBC may eventually lead to cirrhosis and its consequent complications. In the 1980s, PBC was the leading indication for liver transplantation. Ursodeoxycholic acid is the only US FDA-approved therapeutic agent for PBC. Clinical trials have shown that the use of ursodeoxycholic acid in PBC results in reduction of liver biochemistries, a delay in histological progression, a delay in the development of varices and improvement in survival without liver transplantation.

Original languageEnglish (US)
Pages (from-to)1667-1678
Number of pages12
JournalExpert Review of Clinical Immunology
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2014

Fingerprint

Biliary Liver Cirrhosis
Ursodeoxycholic Acid
Liver Transplantation
Intrahepatic Bile Ducts
Antibodies
Varicose Veins
Pruritus
Biochemistry
Fatigue
Liver Diseases
Fibrosis
Clinical Trials
Liver
Incidence

Keywords

  • Antimitochondrial antibody
  • Liver transplantation
  • Primary biliary cirrhosis
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Diagnosis and management of primary biliary cirrhosis. / Ali, Ahmad H.; Carey, Elizabeth J.; Lindor, Keith D.

In: Expert Review of Clinical Immunology, Vol. 10, No. 12, 01.12.2014, p. 1667-1678.

Research output: Contribution to journalArticle

Ali, Ahmad H. ; Carey, Elizabeth J. ; Lindor, Keith D. / Diagnosis and management of primary biliary cirrhosis. In: Expert Review of Clinical Immunology. 2014 ; Vol. 10, No. 12. pp. 1667-1678.
@article{9d6dea7874bf4b96921ec3749ef3004b,
title = "Diagnosis and management of primary biliary cirrhosis",
abstract = "Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized histologically by destruction of intrahepatic bile ducts and serologically by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC are increasing. Fatigue and pruritus are common symptoms in PBC, although the proportion of asymptomatic PBC is increasing due to the widespread use of screening biochemical tests and antimitochondrial antibody assays. PBC may eventually lead to cirrhosis and its consequent complications. In the 1980s, PBC was the leading indication for liver transplantation. Ursodeoxycholic acid is the only US FDA-approved therapeutic agent for PBC. Clinical trials have shown that the use of ursodeoxycholic acid in PBC results in reduction of liver biochemistries, a delay in histological progression, a delay in the development of varices and improvement in survival without liver transplantation.",
keywords = "Antimitochondrial antibody, Liver transplantation, Primary biliary cirrhosis, Ursodeoxycholic acid",
author = "Ali, {Ahmad H.} and Carey, {Elizabeth J.} and Lindor, {Keith D.}",
year = "2014",
month = "12",
day = "1",
doi = "10.1586/1744666X.2014.979792",
language = "English (US)",
volume = "10",
pages = "1667--1678",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "12",

}

TY - JOUR

T1 - Diagnosis and management of primary biliary cirrhosis

AU - Ali, Ahmad H.

AU - Carey, Elizabeth J.

AU - Lindor, Keith D.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized histologically by destruction of intrahepatic bile ducts and serologically by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC are increasing. Fatigue and pruritus are common symptoms in PBC, although the proportion of asymptomatic PBC is increasing due to the widespread use of screening biochemical tests and antimitochondrial antibody assays. PBC may eventually lead to cirrhosis and its consequent complications. In the 1980s, PBC was the leading indication for liver transplantation. Ursodeoxycholic acid is the only US FDA-approved therapeutic agent for PBC. Clinical trials have shown that the use of ursodeoxycholic acid in PBC results in reduction of liver biochemistries, a delay in histological progression, a delay in the development of varices and improvement in survival without liver transplantation.

AB - Primary biliary cirrhosis (PBC) is a chronic cholestatic liver disease characterized histologically by destruction of intrahepatic bile ducts and serologically by the presence of antimitochondrial antibodies. The incidence and prevalence of PBC are increasing. Fatigue and pruritus are common symptoms in PBC, although the proportion of asymptomatic PBC is increasing due to the widespread use of screening biochemical tests and antimitochondrial antibody assays. PBC may eventually lead to cirrhosis and its consequent complications. In the 1980s, PBC was the leading indication for liver transplantation. Ursodeoxycholic acid is the only US FDA-approved therapeutic agent for PBC. Clinical trials have shown that the use of ursodeoxycholic acid in PBC results in reduction of liver biochemistries, a delay in histological progression, a delay in the development of varices and improvement in survival without liver transplantation.

KW - Antimitochondrial antibody

KW - Liver transplantation

KW - Primary biliary cirrhosis

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=84911018623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911018623&partnerID=8YFLogxK

U2 - 10.1586/1744666X.2014.979792

DO - 10.1586/1744666X.2014.979792

M3 - Article

C2 - 25382237

AN - SCOPUS:84911018623

VL - 10

SP - 1667

EP - 1678

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 12

ER -